Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor

Publisher： Bentham Science Publishers

E-ISSN： 1875-5828|12|1|53-60

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.12, Iss.1, 2015-01, pp. : 53-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivastigmine Transdermal Patch and Physical Exercises for Alzheimer's Disease: A Randomized Clinical Trial

By  

Current Alzheimer Research, Vol. 11, Iss. 6, 2014-07 ,pp. : 532-537

Bentham Science Publishers

Access to resources Recommend Favorite

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian   Blake Lesley   Kagan Ethel   Resnick Malca  

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

On the Molecular Basis Linking Nerve Growth Factor (NGF) to Alzheimer’s Disease

By Capsoni Simona   Cattaneo Antonino  

Cellular and Molecular Neurobiology, Vol. 26, Iss. 4-6, 2006-07 ,pp. : 617-631

Springer Publishing Company

Access to resources Recommend Favorite

Identification of GAB2 as a risk factor for late-onset Alzheimer’s disease

By  

Future Neurology, Vol. 2, Iss. 4, 2007-07 ,pp. : 357-359

Future Medicine

Access to resources Recommend Favorite

Alzheimer’s disease

By Gazzaley Adam   Small Scott A.  

Network: Computation in Neural Systems, Vol. 22, Iss. 1-4, 2011-03 ,pp. : 173-185

Informa Healthcare

Access to resources Recommend Favorite